Molidustat Targets a Synthetic Lethal Vulnerability in APC-Mutant Colorectal Cancer through GSTP1 and PHD2 Co-Inhibition
Ontology highlight
ABSTRACT: APC mutations drive colorectal cancer (CRC) and create dependencies on metabolic and stress-adaptation pathways. To investigate vulnerabilities associated with hydroxylase inhibition in APC-mutant cells, we profiled the proteomic consequences of the clinical PHD2 inhibitor Molidustat using thermal proteome profiling and chemical proteomics. These analyses revealed GSTP1 as an unexpected off-target interactor whose enzymatic activity is directly inhibited by Molidustat. Quantitative proteomics of CRISPR knockout models showed that loss of GSTP1 and PHD2 individually induces partially overlapping stress responses, whereas combined loss produces a synergistic redox-collapse phenotype, characterised by oxidative stress, apoptotic signalling, and impaired proliferation, closely recapitulating the cellular response to Molidustat. Metabolomics confirmed elevated oxidative pressure and altered redox balance in the double knockout. In parallel, Molidustat selectively reduced viability in APC- and KRAS-mutant colonic organoids, an effect not reproduced by other hydroxylase inhibitors. Together, these data identify a GSTP1–PHD2 synthetic lethal interaction and demonstrate that Molidustat exploits this vulnerability, providing a mechanistic basis for its selective activity in APC-mutant CRC.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Cell Culture
DISEASE(S): Colon Cancer
SUBMITTER:
Agata Makar
LAB HEAD: Alex von Kriegsheim
PROVIDER: PXD071906 | Pride | 2026-05-04
REPOSITORIES: Pride
ACCESS DATA